Meeting
2017 ASCO Annual Meeting
A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Thomas Powles
Barts Cancer Institute, London, United Kingdom
Thomas Powles , Karim Fizazi , Silke Gillessen , Charles G. Drake , Dana E. Rathkopf , Sujata Narayanan , Marjorie C. Green , Almut Mecke , Christina Schiff , Christopher Sweeney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT03016312
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS5090)
DOI
10.1200/JCO.2017.35.15_suppl.TPS5090
Abstract #
TPS5090
Poster Bd #
162a
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC.
First Author: Vassiliki Papadimitrakopoulou
Poster
2021 ASCO Annual Meeting
TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC).
First Author: Neeraj Agarwal
Poster
2020 ASCO Virtual Scientific Program
Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial.
First Author: Michael J. Morris
Poster
2020 ASCO Virtual Scientific Program
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study.
First Author: Neeraj Agarwal